Cargando…

Adjuvant Chemotherapy With Sequential Cytokine-Induced Killer (CIK) Cells in Stage IB Non-Small Cell Lung Cancer

For non-small cell lung cancer (NSCLC) patients at stage IB, adjuvant chemotherapy does not improve survival. Evidence suggests that dendritic cell (DC)-activated cytokine-induced killer (DC-CIK) cell therapy in addition to chemotherapy improves survival for stage I–IIIA NSCLC patients after surgery...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Da-Peng, Li, Wei, Feng, Jun, Chen, Kai, Tao, Min
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cognizant Communication Corporation 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7838450/ https://www.ncbi.nlm.nih.gov/pubmed/25706393 http://dx.doi.org/10.3727/096504014X14024160459168

Ejemplares similares

Cytokine-induced killer (CIK) cells: from basic research to clinical translation
por: Guo, Yelei, et al.
Publicado: (2015)

Adoptive Immunotherapy Strategies with Cytokine-Induced Killer (CIK) Cells in the Treatment of Hematological Malignancies
por: Schmeel, Frederic Carsten, et al.
Publicado: (2014)

Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety
por: Ma, Yue, et al.
Publicado: (2012)

Improving Clinical Manufacturing of IL-15 Activated Cytokine-Induced Killer (CIK) Cells
por: Bremm, Melanie, et al.
Publicado: (2019)

Influence of adjuvant chemotherapy on survival for patients with stage IB and IIA non‐small cell lung cancer
por: Zhang, Pei, et al.
Publicado: (2020)

Effect and safety of cytokine-induced killer (CIK) cell immunotherapy in patients with breast cancer: A meta-analysis
por: Hu, Jianxin, et al.
Publicado: (2017)

Overall Survival Analyses following Adjuvant Chemotherapy or Nonadjuvant Chemotherapy in Patients with Stage IB Non-Small-Cell Lung Cancer
por: Tu, Zegui, et al.
Publicado: (2021)

Role of adjuvant treatment in stage IB non-small cell lung carcinoma
por: Park, Cheol-Kyu, et al.
Publicado: (2023)

Thymoglobulin, interferon-γ and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade cultures
por: Bonanno, Giuseppina, et al.
Publicado: (2010)

In-vitro influence of mycophenolate mofetil (MMF) and Ciclosporin A (CsA) on cytokine induced killer (CIK) cell immunotherapy
por: Bremm, Melanie, et al.
Publicado: (2016)

Effect of Adjuvant Chemotherapy on Survival of Patients With 8th Edition Stage IB Non-Small Cell Lung Cancer
por: Xu, Yangyang, et al.
Publicado: (2022)

A Novel Nomogram for Identifying Candidates for Adjuvant Chemotherapy in Patients With Stage IB Non-small Cell Lung Cancer
por: Song, Xue, et al.
Publicado: (2023)

Autologous cytokine‐induced killer (CIK) cells enhance the clinical response to PD‐1 blocking antibodies in patients with advanced non‐small cell lung cancer: A preliminary study
por: Han, Ying, et al.
Publicado: (2020)

Retrospective analysis of the efficacy of adjuvant CIK cell therapy in epithelial ovarian cancer patients who received postoperative chemotherapy
por: Zhou, Yun, et al.
Publicado: (2018)

Efficacy of platinum-based adjuvant chemotherapy in T2aN0 stage IB non-small cell lung cancer
por: Park, Seong Yong, et al.
Publicado: (2013)

Benefit of adjuvant chemotherapy for patients with stage IB non-small cell lung cancer: a systematic review and meta-analysis
por: Wang, Xiaofan, et al.
Publicado: (2021)

Adjuvant chemotherapy or immunotherapy for completely resected stage IB non-small cell lung cancer: still a grey zone?
por: Lee, Kuan-Yu, et al.
Publicado: (2023)

Ground Glass Opacity and Adjuvant Chemotherapy in Pathological Stage IB–IIA Lung Adenocarcinoma
por: Zhai, Wenyu, et al.
Publicado: (2022)

Acute exercise mobilizes NKT-like cells with a cytotoxic transcriptomic profile but does not augment the potency of cytokine-induced killer (CIK) cells
por: Zúñiga, Tiffany M., et al.
Publicado: (2022)

Should adjuvant treatment be offered to patients with stage IB non-small cell lung cancer?
por: Passiglia, Francesco, et al.
Publicado: (2023)

Clinical efficacy of adjuvant chemotherapy in stage IB (< 4 cm) non-small cell lung cancer patients with high-risk factors
por: Choi, Juwhan, et al.
Publicado: (2022)

The combination of dendritic cells-cytotoxic T lymphocytes/cytokine-induced killer (DC-CTL/CIK) therapy exerts immune and clinical responses in patients with malignant tumors
por: Wang, Ying, et al.
Publicado: (2015)

Engineering tandem CD33xCD146 CAR CIK (cytokine-induced killer) cells to target the acute myeloid leukemia niche
por: Alberti, Gaia, et al.
Publicado: (2023)

Effectiveness of adjuvant systemic chemotherapy for intermediate-risk stage IB cervical cancer
por: Matsuo, Koji, et al.
Publicado: (2017)

Cytokine-Induced Killer (CIK) Cells, In Vitro Expanded under Good Manufacturing Process (GMP) Conditions, Remain Stable over Time after Cryopreservation
por: Mareschi, Katia, et al.
Publicado: (2020)

Adjuvant Chemotherapy for the Completely Resected Stage IB Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: He, Jiaxi, et al.
Publicado: (2015)

Fertility-sparing management of a stage IB1 small cell neuroendocrine cervical carcinoma with radical abdominal trachelectomy and adjuvant chemotherapy
por: Singh, Sareena, et al.
Publicado: (2015)

CD4(+) T cells are required to improve the efficacy of CIK therapy in non-small cell lung cancer
por: Liu, Shaochuan, et al.
Publicado: (2022)

A novel nomogram for identifying candidates for adjuvant chemotherapy in patients with stage IB gastric adenocarcinoma
por: Xie, Yangyang, et al.
Publicado: (2023)

Sintilimab maintenance therapy post first-line cytokine-induced killer cells plus chemotherapy for extensive-stage small cell lung cancer
por: Ma, Baozhen, et al.
Publicado: (2022)

SMAC Mimetic BV6 Enables Sensitization of Resistant Tumor Cells but also Affects Cytokine-Induced Killer (CIK) Cells: A Potential Challenge for Combination Therapy
por: Rettinger, Eva, et al.
Publicado: (2014)

CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma
por: Giraudo, Lidia, et al.
Publicado: (2023)

Adjuvant chemotherapy compared with observation in patients with T2aN0 stage IB lung adenocarcinoma
por: Lee, Po-Hsin, et al.
Publicado: (2023)

Sequential Cytokine-Induced Killer Cell Immunotherapy Enhances the Efficacy of the Gemcitabine Plus Cisplatin Chemotherapy Regimen for Metastatic Nasopharyngeal Carcinoma
por: Li, Yin, et al.
Publicado: (2015)

Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy
por: Chen, Ping, et al.
Publicado: (2022)

CIK Cells and HDAC Inhibitors in Multiple Myeloma
por: Stephan, David, et al.
Publicado: (2017)

Adjuvant Chemotherapy for Early Stage Non-Small Cell Lung Cancer
por: Patel, Manali I., et al.
Publicado: (2011)

Adjuvant atezolizumab in Japanese patients with resected stage IB‐IIIA non‐small cell lung cancer (IMpower010)
por: Kenmotsu, Hirotsugu, et al.
Publicado: (2022)

Impact on Survival on Interval between Surgery and Adjuvant Chemotherapy in Completely Resected Stage IB-IIIA Lung Cancer
por: Wang, Bing-Yen, et al.
Publicado: (2016)

Value of adjuvant chemotherapy in patients with resected stage IB solid predominant and solid non‐predominant lung adenocarcinoma
por: Cao, Shuhui, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_t2bas6cq6k5outhm8v96fo3llj